A detailed history of Sage Capital Advisors,Llc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Sage Capital Advisors,Llc holds 1,104 shares of VRTX stock, worth $479,158. This represents 0.11% of its overall portfolio holdings.

Number of Shares
1,104
Previous 1,051 5.04%
Holding current value
$479,158
Previous $411,000 16.55%
% of portfolio
0.11%
Previous 0.1%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 06, 2026

BUY
$402.9 - $437.15 $21,353 - $23,168
53 Added 5.04%
1,104 $479,000
Q3 2025

Oct 07, 2025

BUY
$366.54 - $479.53 $123,157 - $161,122
336 Added 46.99%
1,051 $411,000
Q2 2025

Jul 03, 2025

BUY
$421.16 - $509.5 $48,012 - $58,083
114 Added 18.97%
715 $318,000
Q1 2025

Apr 04, 2025

BUY
$402.49 - $513.76 $19,319 - $24,660
48 Added 8.68%
601 $291,000
Q2 2024

Jul 09, 2024

BUY
$392.81 - $485.53 $11,784 - $14,565
30 Added 5.74%
553 $259,000
Q4 2023

Jan 09, 2024

BUY
$343.0 - $410.68 $179,389 - $214,785
523 New
523 $212,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $111B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Sage Capital Advisors,Llc Portfolio

Follow Sage Capital Advisors,Llc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sage Capital Advisors,Llc, based on Form 13F filings with the SEC.

News

Stay updated on Sage Capital Advisors,Llc with notifications on news.